Zobrazeno 1 - 10
of 23
pro vyhledávání: '"Maarten J. van der Doelen"'
Autor:
Jeroen H. A. Creemers, Maarten J. van der Doelen, Sandra van Wilpe, Rick Hermsen, Tjitske Duiveman-de Boer, Diederik M. Somford, Marcel J. R. Janssen, J. P. Michiel Sedelaar, Niven Mehra, Johannes Textor, Harm Westdorp
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
BackgroundRadium-223 improves overall survival (OS) in men with bone metastatic castration-resistant prostate cancer (mCRPC). While the exact mechanism behind this survival benefit remains unclear, radium-induced immunological mechanisms might contri
Externí odkaz:
https://doaj.org/article/9681b271f3804ad081b66ebff52e0e79
Autor:
Maarten J. van der Doelen, Irma M. Oving, Dirk N. J. Wyndaele, Jean-Paul van Basten, Frederiek Terheggen, Addy C. M. van de Luijtgaarden, Wim. J. G. Oyen, W. Dick van Schelven, Franchette van den Berkmortel, Niven Mehra, Marcel J. R. Janssen, Judith B. Prins, Winald R. Gerritsen, José A. E. Custers, Inge M. van Oort
Publikováno v:
Prostate Cancer and Prostatic Diseases, 26, 1, pp. 142-150
Background Radium-223 is a registered treatment option for symptomatic bone metastatic castration-resistant prostate cancer (mCRPC). Aim of this multicenter, prospective observational cohort study was to evaluate health-related quality of life (HR-Qo
Autor:
Babette I. Laarhuis, Marcel J.R. Janssen, Michiel Simons, Ludwike W.M. van Kalmthout, Maarten J. van der Doelen, Steffie M.B. Peters, Harm Westdorp, Inge M. van Oort, Geert Litjens, Martin Gotthardt, James Nagarajah, Niven Mehra, Bastiaan M. Privé
Publikováno v:
Clinical Genitourinary Cancer.
Autor:
Clemens Kratochwil, Inge M. van Oort, James Nagarajah, Marcel J.R. Janssen, Samer Ezziddin, Winald R. Gerritsen, Peter H.J. Slootbeek, Maarten J. van der Doelen, Bart de Keizer, Bastiaan M. Privé, Alfred Morgenstern, Ludwike W. M. van Kalmthout, J. Alfred Witjes, Frank Bruchertseifer, Niven Mehra, Martin Gotthardt, Marjolijn J. L. Ligtenberg, Babette I. Laarhuis, Samhita Pamidimarri Naga, Sandra Heskamp
Publikováno v:
Prostate Cancer and Prostatic Diseases, 25, 1, pp. 71-78
Prostate Cancer and Prostatic Diseases, 25, 71-78
Prostate Cancer and Prostatic Diseases, 25, 71-78
Item does not contain fulltext PURPOSE: Prostate-specific membrane antigen radioligand therapy (PSMA-RLT) is a novel treatment for castration-resistant prostate cancer (mCRPC). While the majority of patients responds to PSMA-RLT, with 10-15% having a
Autor:
Sjoerd van Helvert, Niven Mehra, Samhita Pamidimarri Naga, Maren Bormann, Inge M. van Oort, Leonie I. Kroeze, Emmanuel S. Antonarakis, Peter H.J. Slootbeek, Winald R. Gerritsen, Maarten J. van der Doelen, Pedro Isaacsson Velho
Publikováno v:
European Journal of Cancer, 136, 16-24
European Journal of Cancer, 136, pp. 16-24
European Journal of Cancer, 136, pp. 16-24
Purpose Radium-223 is a targeted alpha radiation therapy for metastatic castration-resistant prostate cancer. DNA damage repair (DDR) defective prostate cancers, specifically genetic aberrations leading to homologous recombination deficiency (HRD), a
Autor:
Katja K.H. Aben, Carin A. Uyl-de Groot, Joan van den Bosch, Inge M. van Oort, Saskia van der Meer, Andries M. Bergman, Jules L.L.M. Coenen, Winald R. Gerritsen, Diederik M. Somford, Hans M. Westgeest, Jules Lavalaye, Alphons C.M. van den Bergh, Mathijs P. Hendriks, Maarten J. van der Doelen, Malou C.P. Kuppen, Filiz Celik, Marco B. Polee, Alphonsus J. M. van den Eertwegh
Publikováno v:
Kuppen, M C, Westgeest, H M, van der Doelen, M J, van den Eertwegh, A J, Coenen, J L, Aben, K K, van den Bergh, A C, Bergman, A M, den Bosch, J V, Celik, F, Hendriks, M P, Lavalaye, J, der Meer, S V, Polee, M B, Somford, D M, van Oort, I M, Uyl-de Groot, C A & Gerritsen, W R 2020, ' Real-world outcomes of radium-223 dichloride for metastatic castration resistant prostate cancer ', Future Oncology, vol. 16, no. 19, pp. 1371-1384 . https://doi.org/10.2217/fon-2020-0039
Future Oncology, 16(19), 1371-1384. Future Medicine Ltd.
Future Oncology, 16, 19, pp. 1371-1384
Future oncology, 16(19), 1371-1384. FUTURE MEDICINE LTD
Future Oncology, 16, 1371-1384
Future Oncology, 16(19), 1371-1384. Future Medicine Ltd.
Future Oncology, 16, 19, pp. 1371-1384
Future oncology, 16(19), 1371-1384. FUTURE MEDICINE LTD
Future Oncology, 16, 1371-1384
Item does not contain fulltext Aim: Timing of radium-223 (Ra-223) in metastatic castration-resistant prostate cancer (mCRPC) remains challenging due to alternative options and short window of opportunity. Methods: Ra-223 treated patients in the CAPRI
Autor:
Bastiaan M, Privé, Peter H J, Slootbeek, Babette I, Laarhuis, Samhita Pamidimarri, Naga, Maarten J, van der Doelen, Ludwike W M, van Kalmthout, Bart, de Keizer, Samer, Ezziddin, Clemens, Kratochwil, Alfred, Morgenstern, Frank, Bruchertseifer, Marjolijn J L, Ligtenberg, J Alfred, Witjes, Inge M, van Oort, Martin, Gotthardt, Sandra, Heskamp, Marcel J R, Janssen, Winald R, Gerritsen, James, Nagarajah, Niven, Mehra
Publikováno v:
Prostate cancer and prostatic diseases. 25(1)
Prostate-specific membrane antigen radioligand therapy (PSMA-RLT) is a novel treatment for castration-resistant prostate cancer (mCRPC). While the majority of patients responds to PSMA-RLT, with 10-15% having an exceptional response, approximately 30
Autor:
Winald R. Gerritsen, Monika G. Looijen-Salamon, Inge M. van Oort, Leonie I. Kroeze, Uwe Haberkorn, Frank Bruchertseifer, Clemens Kratochwil, José A. E. Custers, Niven Mehra, Peter H.J. Slootbeek, Maarten J. van der Doelen, Alfred Morgenstern, Marcel J.R. Janssen, James Nagarajah
Publikováno v:
Urologic Oncology-Seminars and Original Investigations, 39, 10, pp. 729.e7-729.e16
Urologic Oncology-Seminars and Original Investigations, 39, 729.e7-729.e16
Urologic Oncology-Seminars and Original Investigations, 39, 729.e7-729.e16
Contains fulltext : 237645.pdf (Publisher’s version ) (Open Access) INTRODUCTION: Targeted alpha-radiation therapy (TAT) with (225)Ac-labeled prostate-specific membrane antigen (PSMA) ligands is a promising novel treatment option for metastatic cas
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e9eacf94286e8dbf9d81c066c59b25af
https://doi.org/10.1016/j.urolonc.2020.12.002
https://doi.org/10.1016/j.urolonc.2020.12.002
Publikováno v:
European Journal of Cancer, 144, pp. 395-396
European Journal of Cancer, 144, 395-396
European Journal of Cancer, 144, 395-396
Item does not contain fulltext
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1206052b7ef7f246ce499433fca1dc4e
https://hdl.handle.net/2066/229525
https://hdl.handle.net/2066/229525
Autor:
Inge M. van Oort, Yuanjun Ma, Agnes Stockhaus, Sten Nilsson, Winald R. Gerritsen, Anders Ullén, Jeffrey Yachnin, Maarten J. van der Doelen, Niven Mehra
Publikováno v:
European Journal of Nuclear Medicine and Molecular Imaging, 48, 3325-3334
European Journal of Nuclear Medicine and Molecular Imaging
European Journal of Nuclear Medicine and Molecular Imaging, 48, 10, pp. 3325-3334
European Journal of Nuclear Medicine and Molecular Imaging
European Journal of Nuclear Medicine and Molecular Imaging, 48, 10, pp. 3325-3334
Purpose Radium-223 is a life-prolonging therapy for castration-resistant prostate cancer (CRPC) patients with symptomatic bone metastases. However, validated biomarkers for response monitoring are lacking. The study aim was to investigate whether ear
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b336c4cf3386fa6826e0f19079641eec
http://hdl.handle.net/2066/237654
http://hdl.handle.net/2066/237654